FDA Spells Out Details Of Premarket Clinical Trial Inspections
This article was originally published in The Gray Sheet
Executive Summary
A final guidance document released by FDA Jan. 8 gives the timetable that device makers can expect when PMA applications and supplements are reviewed by the device center's bioresearch monitoring division